7Baggers
 CureVac: The Hidden Value Of The mRNA Wallet  Seeking Alpha Wed, 01 Oct 2025 09:26:47 GMT
 goldman sachs group inc. decreases stake in curevac n.v. $cvac  MarketBeat Wed, 24 Sep 2025 09:14:40 GMT
 curevac n.v. (nasdaq:cvac) short interest up 26.9% in august  MarketBeat Mon, 22 Sep 2025 08:43:21 GMT
 BioNTech files CureVac acquisition for German approval  MLex Mon, 22 Sep 2025 07:00:00 GMT
 curevac n.v. (nasdaq:cvac) sees large growth in short interest  MarketBeat Sun, 21 Sep 2025 09:59:41 GMT
 CureVac N.V. (NASDAQ:CVAC) Short Interest Up 26.9% in August  MarketBeat Sun, 21 Sep 2025 07:00:00 GMT
 short interest in curevac n.v. (nasdaq:cvac) grows by 26.9%  MarketBeat Sat, 20 Sep 2025 20:36:40 GMT
 curevac n.v. (nasdaq:cvac) short interest update  MarketBeat Thu, 18 Sep 2025 19:50:14 GMT
 nuveen llc takes position in curevac n.v. $cvac  MarketBeat Fri, 12 Sep 2025 02:00:22 GMT
 nuveen llc buys new shares in curevac n.v. $cvac  MarketBeat Thu, 11 Sep 2025 08:26:28 GMT
 nuveen llc takes position in curevac n.v. $cvac  MarketBeat Thu, 11 Sep 2025 07:00:00 GMT
 state of wyoming buys new shares in curevac n.v. $cvac  MarketBeat Sat, 06 Sep 2025 07:00:00 GMT
 curevac sees cash runway into 2028  MSN Thu, 04 Sep 2025 19:14:28 GMT
 published on: 2025-09-04 04:06:36  Newser Thu, 04 Sep 2025 09:06:36 GMT
 published on: 2025-08-29 03:19:08  Newser Fri, 29 Aug 2025 08:19:08 GMT
 published on: 2025-08-29 02:26:04  Newser Fri, 29 Aug 2025 07:26:04 GMT
 curevac’s strategic moves and financial highlights in 2025  The Globe and Mail Wed, 27 Aug 2025 03:58:00 GMT
 curevac’s strategic moves and financial highlights in 2025  TipRanks Tue, 26 Aug 2025 03:54:59 GMT
 curevac’s strategic moves and financial highlights in 2025  TipRanks Mon, 25 Aug 2025 07:00:00 GMT
 published on: 2025-08-24 16:08:39  Newser Sun, 24 Aug 2025 21:08:39 GMT

CureVac N.V
(NASDAQ:CVAC) 

CVAC stock logo

CureVac N.V., a clinical-stage biopharmaceutical company, engages in developing various transformative medicines based on messenger ribonucleic acid (mRNA). Its lead proprietary programs include CV8102 that is in a Phase 1 dose escalating clinical trials for four types of cancers as a monotherapy an...

Founded: 2000
Full Time Employees: 500
CEO: Franz-Werner Haas  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends